Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin81%-0.8pp81.8%-2.3pp84%+0.2pp83.9%-2.4pp86.3%-0.1pp
Operating margin17.5%+4.0pp13.5%+5.3pp8.2%+15.6pp-7.3%-2.4pp-4.9%+3.0pp
Net margin11.7%+4.2pp7.5%+4.9pp2.6%+13.9pp-11.4%-1.6pp-9.8%+2.6pp
Returns
Return on equity66.9%+2.0pp65%+2.8pp62.2%
Efficiency
Asset turnover0.9×+0.1×0.8×+0.1×0.7×+0.1×0.6×0.0×0.6×0.0×
Liquidity
Current ratio3.1×+0.4×2.8×+0.2×2.5×-0.3×2.8×-0.2×+0.3×
Leverage
Debt-to-equity0.2×-0.1×0.3×-0.8×1.1×+0.1×1.1×+0.4×0.6×-3.4×
Net debt / EBITDA-1.8×+0.7×-2.5×+1.3×-3.8×
Per Share
Book value per share$7.78+32.8%$5.86+244%$1.70-11.2%$1.92-41.6%$3.29+525%
Valuation
Market capitalization$43.88B-16.5%$52.54B-12.1%$59.77B+41.1%$42.38B+21.3%$34.95B+15.1%
Price / earnings87.4×-102×188.9×-533×721.9×
Price / sales10.2×-3.9×14.1×-4.5×18.6×+1.4×17.2×+2.3×14.9×+1.4×
Price / book40.8×-25.8×66.6×-189×255.6×+86.4×169.1×+87.1×82×-370×
EV / EBITDA52.6×-39.2×91.8×-90.6×182.4×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Alnylam Pharmaceuticals's profit margins?
Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
Where do Alnylam Pharmaceuticals's ratios come from?
Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.